Does Ultragenyx Pharmaceutical Inc. (RARE) Have Any Gas After Forming This Bearish Double Bottom Pattern?

February 15, 2018 - By Kurt Siggers

Investors sentiment decreased to 1.19 in Q3 2017. Its down 0.65, from 1.84 in 2017Q2. It turned negative, as 17 investors sold Ultragenyx Pharmaceutical Inc. shares while 40 reduced holdings. 15 funds opened positions while 53 raised stakes. 39.75 million shares or 1.85% less from 40.50 million shares in 2017Q2 were reported.
Victory Mngmt reported 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Prudential invested in 17,740 shares or 0% of the stock. Moreover, Artal Group Inc Sa has 0.05% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Sei Invs holds 0% or 2,029 shares in its portfolio. Peak6 Investments Limited Partnership invested in 1,100 shares or 0% of the stock. Federated Pa reported 0.06% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Tortoise Investment Mngmt Ltd Com holds 0.02% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) or 1,045 shares. Tekla Cap Management Limited Liability Corp has invested 0.28% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Swiss Retail Bank reported 67,252 shares. Crestwood Advisors Grp Ltd Liability Com reported 0.1% stake. Fred Alger Management invested 0.09% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Moreover, Mutual Of America Cap Mgmt Limited Liability has 0.03% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Schwab Charles Mngmt has invested 0.01% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Guardian reported 521,035 shares. Citadel Limited Liability reported 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

The chart of Ultragenyx Pharmaceutical Inc. (RARE) shows a double bottom with $44.36 target or 8.00 % below today’s $48.22 share price. The 8 months chart pattern indicates high risk for the $2.26 billion company. It was reported on Feb, 15 by Finviz.com. If the $44.36 price target is reached, the company will be worth $180.80 million less. Double bottoms are rare but powerful chart patterns.

The stock increased 1.24% or $0.59 during the last trading session, reaching $48.22. About 300,293 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 6.49% since February 15, 2017 and is downtrending. It has underperformed by 23.19% the S&P500.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage

Among 21 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 14 have Buy rating, 1 Sell and 6 Hold. Therefore 67% are positive. Ultragenyx Pharmaceutical Inc had 58 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Friday, January 5 by Wedbush. As per Tuesday, December 22, the company rating was initiated by Canaccord Genuity. Stifel Nicolaus maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rating on Friday, November 3. Stifel Nicolaus has “Buy” rating and $85.0 target. The firm has “Hold” rating given on Friday, July 28 by Jefferies. Canaccord Genuity maintained it with “Buy” rating and $9800 target in Friday, July 28 report. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has “Buy” rating given on Friday, July 28 by Stifel Nicolaus. Cowen & Co maintained the stock with “Buy” rating in Monday, December 4 report. On Thursday, September 14 the stock rating was upgraded by Wedbush to “Outperform”. As per Tuesday, September 1, the company rating was initiated by Raymond James. The stock has “Neutral” rating by H.C. Wainwright on Wednesday, April 19.

More important recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Seekingalpha.com which released: “Ultragenyx Pharmaceutical: Buy The Offering” on January 24, 2018, also Globenewswire.com published article titled: “Ultragenyx Appoints Camille L. Bedrosian, MD as Chief Medical Officer and …”, Globenewswire.com published: “Ultragenyx Announces Pricing of Public Offering of Common Stock” on January 24, 2018. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was released by: Globenewswire.com and their article: “Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 …” with publication date: February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: